DSpace About DSpace Software
 

Makerere University Research Repository >
College of Health Sciences >
School of Health Sciences >
Research Articles (Health-Sciences) >

Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/1582

Title: The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda
Authors: Kigozi, Brian K.
Sumba, Samwel
Mudyope, Peter
Namuddu, Betty
Kalyango, Joan
Karamagi, Charles
Odere, Mathew
Katabira, Elly
Mugyenyi, Peter
Ssali, Francis
Keywords: HIV-infected patients
Health care
Antiretroviral Therapy (ART)
CD4 cell counts
Immunological recovery
HIV wasting syndrome
Cryptosporidiosis
Candidiasis
Tuberculosis
HIV/AIDS
Joint Clinical Research Centre
Uganda
Issue Date: 24-Jul-2009
Publisher: BioMed Central
Citation: Kigozi, B.K., Sumba, S., Mudyope, P., Namuddu, B., Kalyango, J., Karamagi, C., Odere, M., Katabira, E., Mugyenyi, P., Ssali, F. (2009). The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda. AIDS Research and Therapy, 6(17)
Abstract: Background: Many HIV-infected patients only access health care once they have developed advanced symptomatic disease resulting from AIDS Defining Conditions (ADCs). We carried out a study to establish the effect of ADCs on immunological recovery among patients initiated on antiretroviral therapy (ART). Methods: A retrospective cohort of 427 HIV-1 patients who were initiated on ART between January 2002 and December 2006 was studied. Data on ADCs was retrieved from Joint Clinical Research Centre (JCRC) data base and backed up by chart reviews. We employed Kaplan-Meier survival curves to estimate median time to 50 CD4 cells/μl from the baseline value to indicate a good immunological recovery process. Cox proportional hazard models were used at multivariate analysis. Results: The median time to gaining 50 CD4 cells/μl from the baseline value after ART initiation was longer in the ADC (9.3 months) compared to the non-ADC group (6.9 months) (log rank test, p = 0.027). At multivariate analysis after adjusting for age, sex, baseline CD4 count, baseline HIV viral load, total lymphocyte count and adherence level, factors that shortened the median time to immunological recovery after ART initiation were belonging to the non-ADC group (HR = 1.31; 95% CI: 1.03–1.28, p = 0.028), adherence to ART of ≥ 95% (HR = 2.22; 95% CI: 1.57–3.15, p = 0.001) and a total lymphocyte count ≥1200 cells/mm3 (HR = 1.84; 95% CI: 1.22–2.78, p = 0.003). A low baseline CD4 count of ≤ 200 cells/μl (HR= 0.52; 95% CI: 0.37–0.77, p = 0.001) was associated with a longer time to immunological recovery. There was no interaction between low CD4 counts and ADC group. Conclusion: Patients with ADCs take longer to regain their CD4 counts due to the defect in the immune system. This may prolong their risk of morbidity and mortality.
URI: http://www.aidsrestherapy.com/content/6/1/17
http://hdl.handle.net/123456789/1582
ISSN: 1742-6405
Appears in Collections:Research Articles (Health-Sciences)

Files in This Item:

File Description SizeFormat
Kigozi-Chs-Res.pdf761KbAdobe PDFView/Open

All items in DSpace are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2005 MIT and Hewlett-Packard - Feedback